If you are not happy with the results below please do another search
Vertex Pharmaceuticals on Wednesday scooped up clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash in the largest acquisition of 2024, targeting autoimmune and inflammatory diseases.
German packaging and medical equipment maker Gerresheimer has contracts with the leading players in the burgeoning weight-loss drugs sector, CEO Dietmar Siemssen said after the company reported first-quarter earnings on Thursday.
Amylyx Pharmaceuticals on Thursday released interim results from its ongoing Phase II HELIOS trial, showing that its lead asset AMX0035 (sodium phenylbutyrate and taurursodiol) improved pancreatic function and glycemic control in adult patients with the rare, inherited neurodegenerative disease Wolfram syndrome.
Drugmaker AstraZeneca plans to raise its annual dividend by 7% for 2024, it said on Thursday, ahead of a shareholder vote on a hefty boost to its chief executive’s pay package.
Nigeria’s health regulator is recalling a batch of Johnson & Johnson children’s cough syrup after finding an unacceptably high level of a potentially fatal toxic substance, it said on Wednesday.
The U.S. Centers for Disease Control and Prevention (CDC) said on Monday bird flu risk to the public remains low even as it asked the state public health officials to be prepared to respond.
GLP-1 receptor agonists—a popular drug class that includes Novo Nordisk’s Ozempic (semaglutide) and Victoza (liraglutide)—do not appear to increase the risk of thyroid cancer, according to a new study published Wednesday in The BMJ.
Preliminary Phase I/II data demonstrated that Merck and Kelun-Biotech’s TROP2-directed antibody-drug conjugate SKB264 can elicit promising disease control and even potentially extend survival among heavily pretreated patients with gastric or gastroesophageal junction cancer, according to an abstract presentation Tuesday at the 2024 American Association for Cancer Research annual meeting.
Created in partnership with individuals living with HS and their dermatologists, this new campaign features stories of those living with HS, informational videos, and interactive tools and resources for those seeking management options, daily care, and information about HS.
Los Angeles-based startup TORL BioTherapeutics on Wednesday closed a $158 million oversubscribed Series B-2 funding round, which will go toward the advancement of its pipeline of novel antibody-drug conjugates for oncology.